Extended Leadership Team
Reginald Brys
Reginald joined Agomab as head of research in February 2022. Prior to this role, Reginald was VP of drug discovery at Galapagos where he oversaw the company’s discovery portfolio, therapeutic area strategy in research and its translational research activities related to early development projects. Under his leadership, the company developed deep portfolios focused on immune-inflammatory,
Torsten Dreier
Torsten is the CDO at Agomab and brings an extensive expertise in developing antibodies and antibody-based drugs with more than 20 years in the pharmaceutical industry. He has a successful track record of progressing 10 antibody products from preclinical research to clinical development, including two (Blincyto and Cablivi) that obtained marketing authorization. Prior to joining
Recent Comments